Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): A study of changes in medical treatment and surgical resection rates

Gut

Volumn 59, Issue 9, 2010, Pages 1200-1206

  Ramadas, A V ^a   Gunesh, S ^a   Thomas, G A O ^a   Williams, G T ^a   Hawthorne, A B ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CROHN DISEASE; DISEASE ASSOCIATION; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE SURGERY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; ABDOMINAL SURGERY; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PRESCHOOL CHILD; TRENDS; UNITED KINGDOM; UTILIZATION; VERY ELDERLY; YOUNG ADULT;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEOPLASMS; WALES; YOUNG ADULT;

EID: 77955096659     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.202101     Document Type: Article

References (27)

1. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl V), v3.
2. Wolters FL, Russel MGVM, Stockbrugger RW. Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther 2004;20:483-96.
3. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007;13:481-9.
4. Summers RW, Swirtz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69.
5. Lemann M, Mary JY, Colombel J-F, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005:128:1812-18. (Pubitemid 40824692)
6. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
7. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. a meta-analysis. Ann Intern Med 1995;123:132-42.
8. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Library, Issue 4 Oxford: Update Software, 2001.
9. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-41.
10. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006;130:650-6.
11. Thomas GA, Millar-Jones D, Rhodes J, et al. Incidence of CD in Cardiff over 60 years: 1986-90 an update. Eur J Gastroenterol Hepatol 1995;7:401-5.
12. Yapp TR, Stenson R, Thomas GAO, et al. Crohn's disease incidence in Cardiff from 1930: an update for 1991-95. Eur J Gastroenterol Heptol 2000;12:1-5.
13. Gunesh S, Thomas GAO, Williams GT, et al. The incidence of CD in Cardiff over the last 75 years: an update for 1996-2005. Aliment Pharmacol Ther 2006;27:211-19.
14. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;24:2-6.
15. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenteroly 2005;19(Suppl A):5-36.
16. Travis SPL, Stange EF, Lemann M, et al. for the European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55(Suppl I):i16-35.
17. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
18. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of paediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008;135:1106-13.
19. Munkholm P, Langholz E, Davidsen M, et al. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993;106:1716-23. (Pubitemid 24002788)
20. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000;231:38-45.
21. Mekhjian HS, Switz DM, Watts HD, et al. National Cooperative Crohn's Disease Study: factors determining recurrence of Crohn's disease after surgery. Gastroenterology 1979;77:907-13.
22. Henriksen M, Jahnsen J, Lygren I, et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 2007;42:602-10.
23. Sands BE, Arsenault JE, Rosen MJ, et al. Risk of early surgery for Crohn's disease: Implications for early treatment strategies. Am J Gastroenterol 2003;98:2712-18.
24. Domenech E, Zabana Y, Garcia-Planella E, et al. Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective study before and after infliximab availability. Aliment Pharmacol Ther 2010;31:233-9.
25. Lazarev M, Ullman T, Schraut WH, et al. Small bowel resection rates in Crohn's disease and the indication for surgery over time: Experience from a large tertiary care center. Inflamm Bowel Dis 2010;16:830-5.
26. Cannom RR, Kaiser AM, Ault GT, et al. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Surg 2009;75:976-80.
27. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcomes of treatments with infliximab in 614 patients with Crohn's disease: results from a single centre cohort. Gut 2009;58:492-500.